BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
BridgeBio Pharma Inc (NASDAQ:BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for…
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $30
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $27 to $30.
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
BridgeBio Pharma Announces Data For BBP-812
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease
- Initial pharmacodynamic results for two
89 Biggest Movers From Friday
Gainers
Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
BridgeBio Pharma Inc (NASDAQ:BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate…